Afatinib: First Global Approval

A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors

(2013) J. B. Vermorken et al.   ANNALS OF ONCOLOGY

First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments

(2013) Bin-Chi Liao et al.   DRUGS

Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer

(2013) John Marshall et al.   Future Oncology

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1)

(2013) Vera Hirsh et al.   Journal of Thoracic Oncology

Clinical perspective of afatinib in non-small cell lung cancer

(2013) Xiaofeng Chen et al.   LUNG CANCER

Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model

(2013) T. Ninomiya et al.   MOLECULAR CANCER THERAPEUTICS

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab

(2012) Gang Chen et al.   BMC Medicine

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

(2012) Martin Schuler et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

(2012) Nancy U. Lin et al.   BREAST CANCER RESEARCH AND TREATMENT

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

(2012) Michael S. Gordon et al.   INVESTIGATIONAL NEW DRUGS

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors

(2012) A. H. Awada et al.   INVESTIGATIONAL NEW DRUGS

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

(2012) John Marshall et al.   INVESTIGATIONAL NEW DRUGS

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

(2012) Vincent A Miller et al.   LANCET ONCOLOGY

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

(2012) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

(2012) J. De Grève et al.   LUNG CANCER

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers

(2011) Peter Stopfer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)

(2011) H. Murakami et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Role of Genotyping in Non-Small Cell Lung Cancer Treatment

(2011) Laura Bonanno et al.   DRUGS

Management of Recurrent Head and Neck Cancer

(2011) Bruce E. Brockstein   DRUGS

The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer

(2011) Giulio Metro et al.   Expert Review of Anticancer Therapy

Afatinib (BIBW 2992) development in non-small-cell lung cancer

(2011) Vera Hirsh   Future Oncology

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

(2010) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE